GIM
PCRX icon

Granahan Investment Management’s Pacira BioSciences PCRX Stock Holding History

Granahan Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,490
Closed -$1.36M – 197
2021
Q2 		$1.36M Buy
22,490
+7,012
+45% +$444K 0.03% 185
2021
Q1 		$1.08M Sell
15,478
-214,533
-93% -$15.3M 0.02% 181
2020
Q4 		$13.8M Sell
230,011
-16,719
-7% -$979K 0.31% 74
2020
Q3 		$14.8M Sell
246,730
-22,933
-9% -$1.33M 0.5% 57
2020
Q2 		$14.1M Buy
269,663
+56,650
+27% +$2.37M 0.51% 57
2020
Q1 		$7.14M Buy
213,013
+43,722
+26% +$1.82M 0.38% 71
2019
Q4 		$7.67M Buy
+169,291
New +$7.19M 0.35% 75
2019
Q1 		– Sell
-133,693
Closed -$5.75M – 200
2018
Q4 		$5.75M Sell
133,693
-24,343
-15% -$1.14M 0.41% 73
2018
Q3 		$7.77M Sell
158,036
-30,050
-16% -$1.3M 0.42% 75
2018
Q2 		$6.03M Buy
188,086
+20,617
+12% +$712K 0.36% 86
2018
Q1 		$5.22M Sell
167,469
-4,683
-3% -$167K 0.38% 89
2017
Q4 		$7.86M Buy
172,152
+3,688
+2% +$146K 0.62% 56
2017
Q3 		$6.33M Buy
168,464
+27,609
+20% +$1.11M 0.53% 73
2017
Q2 		$6.72M Buy
140,855
+8,190
+6% +$380K 0.62% 54
2017
Q1 		$6.05M Sell
132,665
-503,815
-79% -$21.8M 0.61% 59
2016
Q4 		$20.6M Sell
636,480
-34,130
-5% -$1.14M 0.71% 53
2016
Q3 		$22.9M Buy
670,610
+462,110
+222% +$18.1M 0.75% 41
2016
Q2 		$7.03M Buy
208,500
+49,500
+31% +$2.43M 0.26% 131
2016
Q1 		$8.42M Buy
159,000
+68,300
+75% +$3.99M 0.31% 111
2015
Q4 		$6.96M Sell
90,700
-91,100
-50% -$5.16M 0.24% 130
2015
Q3 		$7.47M Buy
+181,800
New +$11.1M 0.23% 140

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Granahan Investment Management's PCRX Position: Q3 2021 in Review

Granahan Investment Management sold out of Pacira BioSciences (PCRX) in Q3 2021, closing a stake of 22,490 shares — an estimated $1.36M sold.

Granahan Investment Management first reported a position in PCRX in Q3 2015 and held it in 21 quarters. The position peaked at $22.9M in Q3 2016. 259 funds tracked by Wall St. Rank hold PCRX as of Q3 2021.

  • Granahan Investment Management reported no remaining Pacira BioSciences position as of Q3 2021 after selling out during the quarter.
  • Granahan Investment Management sold 22,490 Pacira BioSciences shares in Q3 2021, an estimated $1.36M.
  • Granahan Investment Management first reported a position in Pacira BioSciences in Q3 2015 and held it in 21 quarters.
  • Granahan Investment Management's Pacira BioSciences position peaked at $22.9M in Q3 2016.
  • 259 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2021.

Based on Granahan Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.